Remove 2009 Remove DNA Remove Packaging
article thumbnail

Ensuring reliable assays: Why the ideal microplate is an invisible one

Drug Discovery World

So Aurora Discovery was formed, which operated until 2009 when we merged the business with Nexus Biosystems. But it comes with surface charge that will absorb proteins, DNA, and other things, unless you do something to treat that surface. Everything is packaged in antistatic bags to dissipate any static that might become relevant.

article thumbnail

Medicines Patent Pool signs sublicences with Aurobindo, Cipla and Viatris to produce generic versions of ViiV Healthcare’s innovative long-acting HIV prevention medicine

The Pharma Data

Unitaid is working with implementing partners to ensure optimal use as part of a PrEP package that enables choice, and with the Coalition and other international partners to make long-acting PrEP options equitably accessible as quickly as possible.” Cabotegravir LA for PrEP is an integrase strand transfer inhibitor (INSTI).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Everything Wrong with Mouse Studies (Kinda)

Codon

In 2009, a small group of Dutch biologists rounded up some lab mice, stabbed them with needles, and harvested their blood. There are even differences in how their genomic DNA is packaged inside of neurons. DNA differences accumulate over generations of breeding. Nobody really knows why.

DNA 52
article thumbnail

Analysis Chemical Thank You What we expect the EPA to do in April 2024

Agency IQ

The AWIA, Section 2009(a), also revises the scope of a consolidation plan under the Safe Drinking Water Act (SDWA), subsection 1414(h)(1), to include a contract for significant managerial or administrative functions of a PWS.

article thumbnail

Blackburn – That’s Just Plain Wrong

Drug & Device Law

555 (2009), relied upon to limit impossibility preemption. (B) one HDPE resin to another HDPE resin) of a packaging component that may affect the impurity profile of the drug product. That’s why we have labels. The regulation also provides certain exceptions, such as “(C)(d)(iii),” which is the CBE exception that Wyeth v.

FDA 59